Edgar Filing: Express Scripts Holding Co. - Form 425

Express Scripts Holding Co. Form 425 August 06, 2018

FILED BY EXPRESS SCRIPTS HOLDING COMPANY

PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933

AND DEEMED FILED PURSUANT TO RULE 14a-12

UNDER THE SECURITIES EXCHANGE ACT OF 1934

SUBJECT COMPANY: EXPRESS SCRIPTS HOLDING COMPANY / CIGNA CORPORATION

COMMISSION FILE NO. 001-35490

The following is a transcript of a video that Cigna Corporation added to the deal website, www.advancinghealthcare.com:

Cigna Express Scripts Interview Video

Health Care Today

Scott Josephs: Healthcare needs to be simple. It should be simple for patients to access high-quality health care. It should be simple for providers to deliver high-quality health care.

Steve Miller: Yeah, the combination of Express Scripts and Cigna truly is what America is looking for to transform health care. The frustration out there is incredible. It s the friction, it s the fragmentation, it s the expense, and it s not delivering the quality we want.

Rene Lindsay: What I see today is that patients who may be very sick, and taking specialty medications, are still very savvy. They want affordable care, but they don t want to give up quality. So by connecting care, we re able to deliver that.

Scott Josephs: We want the patient to have the tools they need to take better care of themselves, and a doctor who is appropriately incentivized to care about their medical health, to care about what medications they re taking, what medications they re not taking, and frankly, how their health care is impacting them emotionally.

Chrissa Tibbets: You want to put yourself in the shoes of the patient that you re working with so that you can help create the best care plan for them. What are their specific lifestyle needs? How can you support them the best? And you re treating them as a whole individual and working with them in that regard.

Our Future Vision

Steve Miller: The Cigna Express Scripts database will probably be the largest in health care. When you can take that and you add analytics to it, so you make data into knowledge and knowledge into actions, it s going to be incredibly powerful for physicians, payers, and patients.

Rene Lindsay: When we think about all of these insights that we re receiving and combining and integrating medical, and pharmacy, and lab values, and behavioral, we get a more holistic picture of the patient.

Edgar Filing: Express Scripts Holding Co. - Form 425

Sarah Hopkins: By being able to coordinate care with physicians, nurses, social workers, we can put those pieces together, provide more focused and more specific patient health care, provide better interventions, and have better health outcomes for the patient.

Scott Josephs: The lowest cost disease is one that never occurs. If someone has a condition, addressing it and attacking it before it spreads, before it becomes rampant, that s the holy grail. By giving the doctor the right information at the point of care, that s a recipe for a powerful, positive outcome.

To find out more, visit advancinghealthcare.com

* * *

FORWARD LOOKING STATEMENTS

Cautionary Notes on Forward Looking Statements

Information included or incorporated by reference in this communication, and information which may be contained in other filings with the Securities and Exchange Commission (the SEC) and press releases or other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements of plans, objectives, expectations (financial or otherwise) or intentions.

Forward-looking statements, including as they relate to Express Scripts Holding Company or Cigna Corporation, the management of either such company or the transaction, involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Express Scripts Holding Company and Cigna Corporation do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:

the inability of Express Scripts Holding Company and Cigna Corporation to obtain stockholder or regulatory approvals required for the merger or the requirement to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals;
a longer than anticipated time necessary to consummate the proposed merger;
problems regarding the successful integration of the businesses of Express Scripts Holding Company and Cigna Corporation;
unexpected costs regarding the proposed merger;
diversion of management s attention from ongoing business operations and opportunities;
potential litigation associated with the proposed merger;
the ability to retain key personnel;
the availability of financing;

effects on the businesses as a result of uncertainty surrounding the proposed merger; and

Edgar Filing: Express Scripts Holding Co. - Form 425

the industry may be subject to future risks that are described in SEC reports filed by Express Scripts Holding Company and Cigna Corporation.

You should carefully consider these and other relevant factors, including those risk factors in this communication and other risks and uncertainties that affect the businesses of Express Scripts Holding Company and Cigna Corporation described in their respective filings with the SEC, including the preliminary joint proxy statement / prospectus contained in the Form S-4 of Halfmoon Parent, Inc. (Holdco), which was filed with the SEC on May 16, 2018, when reviewing any forward-looking statement. These factors are noted for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either foregoing lists, or the risks identified in SEC filings, to be a complete discussion of all potential risks or uncertainties.

IMPORTANT INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In connection with the proposed transaction, on May 16, 2018, Holdco has filed a registration statement on Form S-4 that included a joint proxy statement of Cigna Corporation and Express Scripts Holding Company that also constitutes a prospectus of Holdco. The registration statement was declared effective by the SEC on July 16, 2018, and Cigna Corporation and Express Scripts Holding Company commenced mailing the definitive joint proxy

statement/prospectus to the respective stockholders of Cigna Corporation and Express Scripts Holding Company on or about July 17, 2018. Cigna Corporation and Express Scripts Holding Company also plan to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AND THE DEFINITIVE VERSIONS THEREOF (WHEN THEY BECOME AVAILABLE), CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN AND WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the preliminary materials filed on May 16, 2018, the definitive version of the joint proxy statement/prospectus (when it becomes available) and other relevant documents filed by Holdco, Cigna Corporation and Express Scripts Holding Company with the SEC at the SEC s website at www.sec.gov. Copies of documents filed with the SEC by Cigna Corporation will be available free of charge on Cigna Corporation s website at www.cigna.com or by contacting Cigna Corporation s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts Holding Company will be available free of charge on Express Scripts Holding Company s website at www.express-scripts.com or by contacting Express Scripts Holding Company s Investor Relations Department at (314) 810-3115.

PARTICIPANTS IN THE SOLICITATION

Cigna Corporation (and, in some instances, Holdco) and Express Scripts Holding Company and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction under the rules of the SEC. Investors may obtain information regarding the names, affiliations and interests of directors and executive officers of Cigna Corporation (and, in some instances, Holdco) in Cigna Corporation s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 28, 2018, its definitive proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 16, 2018, and the definitive joint proxy statement / prospectus contained in the Form S-4, which was declared effective by the SEC on July 16, 2018. Investors may obtain information regarding the names, affiliations and interests of Express Scripts Holding Company s directors and executive officers in Express Scripts Holding Company s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 27, 2018, its definitive proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 29, 2018, and the definitive joint proxy statement / prospectus contained in the Form S-4, which was declared effective by the SEC on July 16, 2018. You may obtain free copies of these documents at the SEC s website at www.sec.gov. Copies of documents filed with the SEC by Cigna Corporation will be available free of charge on Cigna Corporation s website at www.cigna.com or by contacting Cigna Corporation s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts Holding Company will be available free of charge on Express Scripts Holding Company s website at www.express-scripts.com or by contacting Express Scripts Holding Company s Investor Relations Department at (314) 810-3115. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the joint proxy statement / prospectus and will be contained in other relevant materials to be filed with the SEC regarding the proposed transaction if and when they become available. Investors should read the preliminary joint proxy statement / prospectus, and the definitive version thereof (when it becomes available), carefully and in its entirety before making any voting or investment decisions.

NO OFFER OR SOLICITATION

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.